BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.
IPO Year: 1999
Exchange: NASDAQ
Website: biomarin.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/17/2024 | $104.00 → $72.00 | Outperform → Neutral | Robert W. Baird |
5/14/2024 | $113.00 | Outperform | Evercore ISI |
11/15/2023 | $100.00 | Overweight | Wells Fargo |
10/23/2023 | $82.00 | Underperform → Mkt Perform | Bernstein |
9/28/2023 | Mkt Perform | Raymond James | |
9/18/2023 | $120.00 | Buy | UBS |
7/27/2023 | $95.00 | Sector Perform | Scotiabank |
7/5/2023 | $102.00 | Market Perform → Outperform | BMO Capital Markets |
6/14/2023 | $120.00 | Outperform | Credit Suisse |
3/21/2023 | $81.00 | Underperform | Bernstein |
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
10-Q - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
ARS - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
DEF 14A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
DEFA14A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
10-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
Biomarin Pharmaceutical's (NYSE:BMRN) short percent of float has risen 17.39% since its last report. The company recently reported that it has 3.56 million shares sold short, which is 1.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.12 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Shor
9 analysts have expressed a variety of opinions on Biomarin Pharmaceutical (NASDAQ:BMRN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 5 4 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 3 3 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $99.67, a high estimate of $115.00, and a low estimate of $72.00. A negative shift
Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $110 to $115.
New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of Observation in Children with AchondroplasiaPhase 2 and 3 Data on VOXZOGO Demonstrate Safety, Efficacy and Impact on Proportionality and Health-Related Quality of Life for Children with AchondroplasiaNew Research Underscores Unmet Medical Needs of People with HypochondroplasiaSAN RAFAEL, Calif., June 17, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the presentation of new data from an investigator-led analysis of the Phase 2 111-205 study, which demonstrate that children with achondroplasia treated with VOXZOGO® experienced increase
Data from Longest and Largest Hemophilia Gene Therapy Study Show Durable and Sustained Bleed Control and Factor VIII Expression Maintained Four Years Post-ROCTAVIAN InfusionAdditional Data Show Meaningful Impact of ROCTAVIAN on Health-Related Quality of Life (HRQoL) SAN RAFAEL, Calif., June 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that new data supporting the long-term safety and efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) will be presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand, June 22-26, 2024.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume CERE PUT TRADE NEUTRAL 07/19/24 $40.00 $56.0K 3 2.9K LFMD CALL SWEEP BULLISH 11/15/24 $7.50 $54.4K 2.
Biomarin Pharmaceutical's (NYSE:BMRN) short percent of float has fallen 4.81% since its last report. The company recently reported that it has 3.74 million shares sold short, which is 1.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.71 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Shor
These 10 large-cap stocks were the worst performers last week. Are they in your portfolio? NICE Ltd (NASDAQ:NICE) shares tumbled 15.60% after the company reported Q1 financial results and issued Q2 adjusted revenue guidance with its midpoint below estimates. Petroleo Brasileiro S.A. (NYSE:PBR) shares plummeted 13.03% after Q1 sales missed consensus. Also, Brazil’s President Luiz Inacio Lula da Silva fired CEO Jean Paul Prates following a dispute over the dividends. Comfort Systems USA, Inc. (NYSE:FIX) stock fell 8.37% in the last week. Li Auto Inc. (NASDAQ:LI) shares fell 7.64%, possibly in reaction to reports that Biden is preparing tariffs on the Chinese EV and solar sectors
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut the price target for Globant S.A. (NYSE:GLOB) from $290 to $238. Piper Sandler analyst Arvind Ramnani reiterated an Overweight rating. Globant shares fell 0.3% to close at $177.73 on Thursday. See how other analysts view this stock. Baird slashed the price target for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from $104 to $72. Baird analyst Joel Beatty downgraded the stock from Outperform to Neutral. BioMarin Pharmaceutical shares fell 4.3% to close at $76.97 on Thursday. See how
Robert W. Baird downgraded BioMarin Pharmaceutical from Outperform to Neutral and set a new price target of $72.00 from $104.00 previously
Evercore ISI initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $113.00
Wells Fargo initiated coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $100.00
Bernstein upgraded BioMarin Pharmaceutical from Underperform to Mkt Perform and set a new price target of $82.00
Raymond James initiated coverage of BioMarin Pharmaceutical with a rating of Mkt Perform
UBS initiated coverage of BioMarin Pharmaceutical with a rating of Buy and set a new price target of $120.00
Scotiabank initiated coverage of BioMarin Pharmaceutical with a rating of Sector Perform and set a new price target of $95.00
BMO Capital Markets upgraded BioMarin Pharmaceutical from Market Perform to Outperform and set a new price target of $102.00
Credit Suisse resumed coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $120.00
Bernstein initiated coverage of BioMarin Pharmaceutical with a rating of Underperform and set a new price target of $81.00
First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings per Share of $0.71 (+18% Y/Y) VOXZOGO® Net Product Revenues of $153 Million in Q1'24 (+74% Y/Y); Children Treated Increased Over 100% Y/Y For Full-year 2024 Guidance, Total Revenues Reaffirmed, Non-GAAP Operating Margin and Non-GAAP EPS Raised R&D Prioritization Results in Acceleration of Three Highest Value Programs Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., April 24, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the q
SAN RAFAEL, Calif., April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-330-3556International Dial-in Number: 646-960-0826Conference Call ID: 1816377 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Playback
Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and Non-GAAP Diluted Earnings per Share of $2.08 (+36% Y/Y) VOXZOGO® Net Revenues of $146 Million in Q4'23 (+118% Q/Q) and $470 Million for FY'23 (+178% Y/Y) BioMarin's 2024 Financial Outlook Reflects Anticipated Double-digit Total Revenue Growth, Significant Non-GAAP Operating Margin Expansion, and Non-GAAP Earnings Per Share Growing Faster than Revenues Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., Feb. 22, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the fourth quar
SAN RAFAEL, Calif., Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 4:30 p.m. ET to discuss fourth quarter and full-year 2023 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-330-3073International Dial-in Number: 646-960-0683 Conference Call ID: 1816377 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 647-
VOXZOGO® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased Full Year 2023 GuidancePivotal Program with VOXZOGO in New, Potential Second Indication, Hypochondroplasia, to Begin in the Fourth Quarter of 2023U.S. Approval of ROCTAVIAN™ Received in the Second Quarter and Commercial Launch Underway; Commercial Launch in Europe Making ProgressFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 % Change 2023 2022 % Change Total Revenues $ 595.3 $ 533.8 12 % $ 1,191.7 $ 1,053.2 13 % Total Enzyme Product Revenues (1) $ 420.8 $ 425.7 (1
SAN RAFAEL, Calif., July 12, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, July 31, at 4:30 p.m. ET to discuss second-quarter 2023 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-886-7786International Dial-in Number: 416-764-8658Conference Call ID: 93773398 U.S. / Canada Replay Dial-in Number: 877-674-7070International Replay Dial-in Number: 416-764-8692Playba
ROCTAVIAN is a One-Time, Single-Dose Treatment Available for Adults with Severe Hemophilia A to Control Bleeds ROCTAVIAN's Approval was Based on Durability, Efficacy and Safety Results from the Largest and Longest Phase 3 Study for a Gene Therapy for Hemophilia Majority of Patients Continued to Respond to ROCTAVIAN Treatment over 3 Years Conference Call and Webcast to be Held at 4:30 p.m. Eastern Time on Thursday, June 29, 2023 SAN RAFAEL, Calif., June 29, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that the United States Food and Drug Administration (FDA) approve
Growth of VOXZOGO® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 GuidanceFull-year 2023 Top-line and Bottom-line Financial Guidance Reaffirmed; ROCTAVIAN™ Net Product Revenue Guidance Adjusted for Full-year 2023In Germany, Growing Pipeline of People with Severe Hemophilia A Getting Tested for ROCTAVIAN Treatment Eligibility; ROCTAVIAN U.S. Launch Preparations Underway Ahead of June 30 Prescription Drug User Fee Act (PDUFA) Target Action DateFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2023 2022 % Change Total Revenues $ 596.4 $ 519.4 15 % Total Enzyme Product Revenues (1
SAN RAFAEL, Calif., April 13, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 26, at 4:30 p.m. ET to discuss first-quarter 2023 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 800-831-4163International Dial-in Number: 213-992-4616 U.S. / Canada Replay Dial-in Number: 800-645-7964International Replay Dial-in Number: 757-849-6722Playback ID: 9184# Interested
VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 BillionIn 2023, More than 15% Growth in Total Revenues and Approximately 30% Growth in Net Income Expected Based on Mid-point of Today's Full-year Guidance; VOXZOGO Revenues Expected to More than DoubleROCTAVIAN European Commercial Launch and U.S. Launch Preparations Both Underway; 3-year Analysis from Phase 3 ROCTAVIAN Study in Adults with Severe Hemophilia A Recently Submitted to the FDAFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 % Change 2022 2021 % Change Total Revenues $ 537.5 $
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries Appointment Effective May 20, 2024 SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer. Ms. Hubbard is a proven leader who brings to BioMarin more than 20 years of experience in the biopharmaceutical and
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
SAN RAFAEL, Calif., Dec. 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles, to its Board of Directors effective January 1, 2022. "We are thrilled to have Mark join BioMarin's Board of Directors. He is a renowned leader in the biopharmaceutical industry, bringing deep operational, financial, business development and commercial experience to our exceptional board," said Jean-Jacques Bienaimé, Chairman and Chief
SAN RAFAEL, Calif., Feb. 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Goldman Sachs partner and executive in the life sciences industry, Maykin Ho, Ph.D., to its Board of Directors. "We are thrilled to welcome Maykin to BioMarin's Board of Directors. She brings a breadth and depth of experience in the healthcare industry and finance to an already exceptional board," said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer at BioMarin. "Maykin brings an important perspective to support BioMarin's growth trajectory as we strive to address the unmet m
New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of Observation in Children with Achondroplasia Phase 2 and 3 Data on VOXZOGO Demonstrate Safety, Efficacy and Impact on Proportionality and Health-Related Quality of Life for Children with Achondroplasia New Research Underscores Unmet Medical Needs of People with Hypochondroplasia SAN RAFAEL, Calif., June 17, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the presentation of new data from an investigator-led analysis of the Phase 2 111-205 study, which demonstrate that children with achondroplasia treated with VOXZOGO® experienced incre
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
Data from Longest and Largest Hemophilia Gene Therapy Study Show Durable and Sustained Bleed Control and Factor VIII Expression Maintained Four Years Post-ROCTAVIAN Infusion Additional Data Show Meaningful Impact of ROCTAVIAN on Health-Related Quality of Life (HRQoL) SAN RAFAEL, Calif., June 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that new data supporting the long-term safety and efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) will be presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand, June 22-26, 2024.
SAN RAFAEL, Calif., May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference. About
Investigator-Sponsored Phase 2 Study Demonstrated Positive Results in Children with Noonan Syndrome, Idiopathic Short Stature and Other Growth-Related Conditions BioMarin-Sponsored Phase 3 Data Show Notable Mean Annualized Growth Velocity Increases in Children with Achondroplasia Who Started Treatment During Adolescence SAN RAFAEL, Calif., May 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in children with achondroplasia, as well as positive data for investigational uses in growth-related conditions, including idiopathic short stature (ISS) and Noonan syndrome, were presented at t
First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings per Share of $0.71 (+18% Y/Y) VOXZOGO® Net Product Revenues of $153 Million in Q1'24 (+74% Y/Y); Children Treated Increased Over 100% Y/Y For Full-year 2024 Guidance, Total Revenues Reaffirmed, Non-GAAP Operating Margin and Non-GAAP EPS Raised R&D Prioritization Results in Acceleration of Three Highest Value Programs Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., April 24, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the q
SAN RAFAEL, Calif., April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-330-3556International Dial-in Number: 646-960-0826Conference Call ID: 1816377 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Playback
Investigator-Sponsored Phase 2 Study Demonstrated Positive Results for VOXZOGO in Children with Hypochondroplasia New Analyses Highlight VOXZOGO 7-year Data and Improvement on Quality of Life in Children with Achondroplasia SAN RAFAEL, Calif., March 12, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024. Researchers will also present data from Phase 2 and Phase 3 studies of the medi
Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries Appointment Effective May 20, 2024 SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer. Ms. Hubbard is a proven leader who brings to BioMarin more than 20 years of experience in the biopharmaceutical and
- Cowen 44th Annual Healthcare Conference on March 5- Leerink Partners Global Biopharma Conference on March 11- Jefferies Biotech on the Bay Summit on March 12- Barclays 26th Annual Global Healthcare Conference on March 12 SAN RAFAEL, Calif., March 1, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced management is scheduled to participate in four upcoming investor conferences in March. Cowen 44th Annual Healthcare Conference (Boston, MA) Tuesday, March 5th, Brian Mueller, Executive Vice President, Chief Financial Officer is